What this study is
The purpose of this study is about assessing the utilization of a mobile phone application (app), designed to improve the menopause experience of midlife women experiencing related symptoms and its association with menopause-related health care utilization
What's being tested
- EMMII
Intervention · OTHER
The tool/app, consists of educational components designed to enable women to more effectively identify menopause symptoms and feel confident in seeking treatment to address their symptoms. The tool/app also produces a tailored menopause discussion guide for patients to bring to their primary care appointment.
- Comparison Group
Intervention · OTHER
Receive educational menopause pamphlet describing menopause symptoms and evidence-based treatment options.
Study details
- Official title
- Evaluation of a Mobile Phone Application Tool for Menopause Symptom Management
- Sponsor
- Mayo Clinic
- Conditions
- Menopausal Symptoms · Menopause Symptom Management
- Enrolling
- 450 people
- Starts
- 2025-05-07
- Est. completion
- 2027-12-15
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 24 Years – 80 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- For Patient Enrollment:
- Women between the ages of 45 and 55
- English speaking (app only available in English)
- Able to provide informed consent
- Experiencing menopause symptoms, which will be assessed by a Menopause Rating Scale (MRS) survey score of ≥ 5
- Has an upcoming Mayo Clinic primary care appointment within 3 weeks of the enrollment and the MRS survey
You can't join if
- Lack of willingness to engage with app
- Inability to provide informed consent
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openMayo Clinic
Rochester, Minnesota, United States
Study team
Sponsor
Mayo Clinic
Study ID 24-013662
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.